DNA vaccines for farm animals, in particular bovines and porcines

Abstract

DNA vaccine against a pathogen affecting farm animals, in particular bovines or porcines, comprising a plasmid containing a nucleotide sequence encoding an immunogen of a pathogen of the animal species considered, under conditions allowing the in vivo expression of this sequence, and a cationic lipid containing a quaternary ammonium salt, of formula in which R1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group, this lipid being preferably DMRIE.

1 - 83 . (canceled)  
     
     
         84 . A DNA vaccine against a porcine pathogen, wherein the porcine pathogen is porcine herpesvirus or Aujeszky's disease (pseudorabies virus or PRV), porcine reproductive respiratory syndrome virus (or PRRSV), swine influenza virus (or SIV), conventional hog cholera virus (or HCV) or a parvovirus in porcines, comprising at least one plasmid that contains and expresses in a porcine host cell a nucleotide sequence encoding an immunogen of the porcine pathogen, and a cationic lipid containing a quaternary ammonium salt, of the formula  
       
         
           
           
               
               
           
         
       
       in which R 1  is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R 2  is an aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group.  
     
     
         85 . The vaccine according to  claim 84 , further comprising DOPE.  
     
     
         86 . The vaccine according to  claim 84 , further comprising porcine GM-CSF.  
     
     
         87 . The vaccine according to  claim 85 , further comprising porcine GM-CSF.  
     
     
         88 . The vaccine according to  claim 84 , further comprising an expression vector that contains and expresses in a porcine host cell a nucleotide sequence encoding porcine GM-CSF.  
     
     
         89 . The vaccine according to  claim 85 , further comprising an expression vector that contains and expresses in a porcine host cell a nucleotide sequence encoding porcine GM-CSF.  
     
     
         90 . The vaccine according to  claim 88 , wherein the expression vector is a plasmid.  
     
     
         91 . The vaccine according to  claim 89 , wherein the expression vector is a plasmid.  
     
     
         92 . The vaccine according to  claim 84 , wherein the nucleotide sequence encoding the immunogen of the porcine pathogen has deleted therefrom a portion encoding a transmembrane domain.  
     
     
         93 . The vaccine according to  claim 84 , wherein the plasmid further contains and expresses in a porcine host cell a nucleotide sequence encoding a heterologous tPA signal sequence.  
     
     
         94 . The vaccine according to  claim 84 , wherein the plasmid further contains a stabilizing intron.  
     
     
         95 . The vaccine according to  claim 94 , wherein the intron is intron II of a rabbit beta-globin gene.  
     
     
         96 . The vaccine according to  claim 84  wherein the lipid is DMRIE.  
     
     
         97 . The vaccine according to  claim 85  wherein the lipid is DMRIE.  
     
     
         98 . The vaccine according to  claim 92 , further comprising DOPE.  
     
     
         99 . The vaccine according to  claim 92 , further comprising porcine GM-CSF.  
     
     
         100 . The vaccine according to  claim 92 , further comprising an expression vector that contains and expresses in a porcine host cell a nucleotide sequence encoding porcine GM-CSF.  
     
     
         101 . The vaccine according to  claim 100 , wherein the expression vector is a plasmid.  
     
     
         102 . The vaccine according to  claim 93 , further comprising DOPE.  
     
     
         103 . The vaccine according to  claim 93 , further comprising porcine GM-CSF.  
     
     
         104 . The vaccine according to  claim 93 , further comprising an expression vector that contains and expresses in a porcine host cell a nucleotide sequence encoding porcine GM-CSF.  
     
     
         105 . The vaccine according to  claim 104 , wherein the expression vector is a plasmid.  
     
     
         106 . The vaccine according to  claim 94 , further comprising DOPE.  
     
     
         107 . The vaccine according to  claim 94 , further comprising porcine GM-CSF.  
     
     
         108 . The vaccine according to  claim 94 , further comprising an expression vector that contains and expresses in a porcine host cell a nucleotide sequence encoding porcine GM-CSF.  
     
     
         109 . The vaccine according to  claim 108 , wherein the expression vector is a plasmid.  
     
     
         110 . The vaccine according to  claim 84 , wherein the porcine pathogen is porcine herpesvirus or Aujeszky's disease (pseudorabies virus or PRV).  
     
     
         111 . The vaccine according to  claim 110 , wherein the immunogen is PRV gB, modified by substitution of the PRV gB signal sequence with a human tPA signal sequence, and/or by deletion of the transmembrane domain.  
     
     
         112 . The vaccine according to  claim 110 , wherein the immunogen is PRV gC, modified by substitution of the PRV gC signal sequence with a human tPA signal sequence, and/or by deletion of the transmembrane domain.  
     
     
         113 . The vaccine according to  claim 110 , wherein the immunogen is PRV gD, modified by substitution of the PRV gD signal sequence with a human tPA signal sequence, and/or by deletion of the transmembrane domain.  
     
     
         114 . The vaccine according to  claim 85  comprising a first plasmid that contains and expresses in a porcine host cell a nucleotide sequence encoding porcine pseudorabies virus glycoprotein gB (PRV gB), modified by substitution of the PRV gB signal sequence with a human tPA signal sequence and deletion of the transmembrane domain and contiguous C-terminal portion; a second plasmid that contains and expresses in a porcine host cell a nucleotide sequence encoding PRV gC, modifiedby substitution of the PRV gC signal sequence with a human tPA signal sequence and deletion of the transmembrane domain and contiguous C-terminal portion and a third plasmid that contains and expresses in a porcine host cell a nucleotide sequence encoding PRV gD, modified by substitution of the PRV gD signal sequence with a human tPA signal sequence and deletion of the transmembrane domain and contiguous C-terminal portion; and wherein the lipid is DMRIE, whereby the vaccine comprises DMRIE-DOPE.  
     
     
         115 . The vaccine according to  claim 110 , further comprising DOPE.  
     
     
         116 . The vaccine according to  claim 110 , further comprising porcine GM-CSF.  
     
     
         117 . The vaccine according to  claim 110 , further comprising an expression vector that contains and expresses in a porcine host cell a nucleotide sequence encoding porcine GM-CSF.  
     
     
         118 . The vaccine according to  claim 117 , wherein the expression vector is a plasmid.  
     
     
         119 . The vaccine of  claim 110  wherein the immunogen is PRV gB.  
     
     
         120 . The vaccine of  claim 110  wherein the immunogen is PRV gC.  
     
     
         121 . The vaccine of  claim 110  wherein the immunogen is PRV gD.